Thymosin β-4 and the β-thymosin family
Thymosin β-4 is a 43-amino-acid, highly-conserved intracellular peptide belonging to the β-thymosin family. It is one of the most abundant intracellular peptides in mammalian cells and its principal recognised molecular function is binding monomeric (G-)actin through a well-characterised binding motif, preventing polymerisation into filamentous (F-)actin. This actin-sequestering activity regulates the equilibrium between G-actin and F-actin — a central determinant of cell shape, motility, and division.
Beyond actin binding, Thymosin β-4 has been characterised extrinsically in wound-healing, endothelial-cell recruitment, angiogenesis, and anti-inflammatory endpoints. The relationship between the actin-binding activity and these tissue-level effects is proposed but not fully worked out — a common feature of the literature on Tβ4 and its fragments.
The TB-500 fragment: LKKTETQ
TB-500 corresponds to the LKKTETQ motif — the seven-residue central region of Thymosin β-4 most directly involved in actin binding. In the preclinical literature, TB-500 is used interchangeably with the term "Tβ4 fragment 17-23" referring to the residue positions in the parent peptide.
The rationale for using the fragment rather than full-length Tβ4 in preclinical work is partly about accessibility (a shorter synthetic peptide is easier and cheaper to produce reliably) and partly about mechanistic interpretability — the fragment isolates the actin-binding motif from the broader Tβ4 sequence that carries additional activity beyond actin binding.
Wound-healing and endothelial-cell research
The most-cited preclinical characterisation of Tβ4 and TB-500 sits in wound-healing models. Reported endpoints include accelerated re-epithelialisation of skin wounds in rodent models, enhanced granulation-tissue formation, and reduced scar area. Corneal-wound and dermal-punch models are commonly used variants of this literature.
Endothelial-cell endpoints connect the wound-healing framework to angiogenesis. TB-500 and Tβ4 have been reported to enhance endothelial-cell migration in transwell and scratch-wound assays, and to promote tube formation in matrigel angiogenesis assays. Vessel-density counts in wound-bed tissue sections from in-vivo studies show consistent, if modest, effects.
Cardiac injury and epicardial-cell research
A distinct line of research has characterised Tβ4 and TB-500 in cardiac injury models — most notably ischaemia-reperfusion and infarct models. Reported endpoints include preservation of cardiac function, reduced infarct size, and recruitment of epicardial-derived progenitor cells to the injured myocardium.
Mechanistically, Tβ4 has been proposed to reactivate embryonic epicardial signalling programs that support cardiomyocyte survival and new-vessel formation. This body of work — largely from a small number of laboratories — is one of the more mechanistically interesting angles on the Tβ4 / TB-500 literature.
Comparative context: TB-500, BPC-157, and GHK-Cu
In the broader tissue-repair peptide landscape, TB-500 sits alongside BPC-157 and GHK-Cu as one of three synthetic peptides commonly studied in overlapping model systems. Each arrives at wound-healing endpoints through a distinct proposed mechanism — TB-500 through actin sequestration and endothelial-cell recruitment, GHK-Cu through copper delivery and matrix signalling, and BPC-157 through mixed cytoprotective and angiogenic activities.
Head-to-head comparative studies are limited; most of what is written about relative activity is inferred from parallel published work in similar models. This is a common gap in the literature and worth being explicit about when framing new research using any of these peptides.
Analytical characterisation and storage
TB-500 is characterised by reversed-phase HPLC for purity and mass spectrometry for identity. The theoretical monoisotopic mass of the free-acid form is approximately 889 Da. As a short, acidic peptide, TB-500 is amenable to standard peptide-characterisation methods; chromatographic conditions should be tuned to resolve any related fragment impurities.
Lyophilised material is stored sealed, desiccated, and cold. Reconstituted material is refrigerated and aliquotted into single-use portions to minimise freeze-thaw exposure. TB-500 is stable enough in solution under standard cold storage that working-concentration solutions can be maintained across a study timeline, provided freeze-thaw cycles are minimised.
Worked examples
Reconstituting a 5 mg TB-500 vial
- 01Bring the sealed vial to room temperature before opening.
- 02Wipe the stopper with an alcohol swab.
- 03Add 2.5 mL of bacteriostatic water for a nominal 2 mg/mL working concentration.
- 04Let the diluent run down the inside wall of the vial. Do not spray onto the solid.
- 05Swirl gently until dissolved.
- 06Label with lot, concentration, diluent, and reconstitution date.
Storage protocol for a multi-week study
- 01Lyophilised material: sealed and desiccated at 2–8 °C short-term or −20 °C long-term.
- 02Reconstituted material: refrigerated at 2–8 °C, aliquotted into single-use portions.
- 03Label every aliquot with lot, concentration, and reconstitution date.
- 04Minimise freeze-thaw cycles — the largest avoidable source of variability across a study.
Frequently asked questions
Is TB-500 the same as Thymosin β-4?
No. TB-500 is a synthetic seven-residue fragment (LKKTETQ) corresponding to the actin-binding motif of the 43-residue Thymosin β-4. The fragment isolates that motif from the broader parent sequence.
What is the actin-binding activity?
Thymosin β-4 (and its LKKTETQ motif) binds monomeric G-actin, preventing polymerisation into F-actin. This regulates the G-actin / F-actin equilibrium — a central determinant of cell shape and motility.
What preclinical models is TB-500 characterised in?
Wound-healing (skin, corneal, dermal-punch), endothelial-cell migration (transwell, scratch, matrigel), and cardiac injury (ischaemia-reperfusion, infarct) models are the most-cited. Both TB-500 and full-length Tβ4 have been used across these systems.
What analytical tests confirm identity and purity?
Reversed-phase HPLC quantifies purity; mass spectrometry confirms identity against the expected molecular weight near 889 Da for the free-acid form. A batch COA should include both.
How should reconstituted TB-500 be stored?
Refrigerated at 2–8 °C, aliquotted into single-use portions to minimise freeze-thaw exposure, and characterised in the specific buffer system used for a given study.
References
Selected published research referenced in this article.
- 01Goldstein AL, Hannappel E, Kleinman HK. Thymosin β4: actin-sequestering protein moonlights to repair injured tissues. Trends Mol Med. 2005;11(9):421–429. PubMed
- 02Malinda KM, Sidhu GS, Mani H, et al. Thymosin β4 accelerates wound healing. J Invest Dermatol. 1999;113(3):364–368. PubMed
- 03Bock-Marquette I, Saxena A, White MD, Dimaio JM, Srivastava D. Thymosin β4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature. 2004;432(7016):466–472. PubMed
- 04Smart N, Risebro CA, Melville AA, et al. Thymosin β4 induces adult epicardial progenitor mobilization and neovascularization. Nature. 2007;445(7124):177–182. PubMed
- 05Philp D, Kleinman HK. Animal studies with thymosin beta, a multifunctional tissue repair and regeneration peptide. Ann N Y Acad Sci. 2010;1194:81–86. PubMed
- 06Sosne G, Qiu P, Christopherson PL, Wheater MK. Thymosin beta 4 suppression of corneal NFκB: a potential anti-inflammatory pathway. Exp Eye Res. 2007;84(4):663–669. PubMed